We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Expanded Access to Venetoclax

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03123029
Recruitment Status : Available
First Posted : April 21, 2017
Last Update Posted : March 14, 2018
Information provided by (Responsible Party):

April 18, 2017
April 21, 2017
March 14, 2018
Expanded Access to Venetoclax
Expanded Access to Venetoclax
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Not Provided
Expanded Access
Individual Patients
  • Chronic Lymphocytic Leukemia (CLL)
  • Multiple Myeloma
  • Acute Myeloid Leukemia (AML)
  • Non-Hodgkin's Lymphoma
Drug: Venetoclax
Venetoclax will be administered orally.
Other Names:
  • ABT-199
  • GDC-0199
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
  • The participant must not be eligible for a venetoclax clinical trial.
  • Pediatric participants may be evaluated on a case by case basis.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact: ABBVIE CALL CENTER 847.283.8955 abbvieclinicaltrials@abbvie.com
Not Provided
Not Provided
Study Director: AbbVie Inc. AbbVie
March 2018